irritable bowel syndrome

Ironwood's Bowel Drug Sales Disappoint

Ironwood's Bowel Drug Sales Disappoint

TheStreet.com

SP-333 Targets Root Cause Of Irritable Bowel Syndrome

SP-333 Targets Root Cause Of Irritable Bowel Syndrome

Motley Fool

Sucampo Announces Approval for Updates to AMITIZA; Endo Health Solutions Stock Halted Following News

Sucampo Announces Approval for Updates to AMITIZA; Endo Health Solutions Stock Halted Following News

Equities.com

Sucampo Pharmaceuticals, Inc. : Sucampo Presents Data for AMITIZA® in the Treatment of Moderate to Very Severe Irritable Bowel Syndrome with Constipation (IBS-C)

Sucampo Pharmaceuticals, Inc. : Sucampo Presents Data for AMITIZA® in the Treatment of Moderate to Very Severe Irritable Bowel Syndrome with Constipation (IBS-C)

4-Traders

Yet Another Delay for Forest Labs

Yet Another Delay for Forest Labs

Yahoo/Zacks

Tioga nabs $10M VC deal amid PhIII for bowel disorder drug

Tioga nabs $10M VC deal amid PhIII for bowel disorder drug

Fierce Biotech

FDA gives fast-track status to Tioga irritable bowel drug

FDA gives fast-track status to Tioga irritable bowel drug

San Diego Union Tribune, CA

News

Salix's IBS drug fails to get FDA nod

Reuters

News

Salix Tanks After Drug Setback

Minyanville